2026 D&O by stage

Best Biotech D&O Architecture - 2026

Biotech D&O architecture is stage-driven. The right structure at pre-IND is the wrong structure at IPO-readiness; the right structure at IPO-readiness is the wrong structure post-IPO. The five archetypes below cover the major stage transitions and what changes at each.

Pre-clinical operators, often pre-revenue, VC-backed; $1M-$10M revenue or pure burn-rate.

Pre-IND biotech D&O

· Primary D&O at $2M-$5M with VC-backed-clinical-stage carrier.

· Side A coverage explicitly included, sized to fund individual indemnification for board members in the event entity indemnification fails.

· No transactional D&O (no public offering activity).

· Coordinate with clinical trial liability if any active studies (typically none at pre-IND).

· Coordinate with employment practices liability for hiring growth.

Typical Texas premium: $15K-$45K annually for a Texas pre-IND biotech.

Clinical-stage operators with active human trials, VC-backed; common at $2M-$20M revenue or burn rate equivalent.

Phase 1-2 clinical-stage D&O

· Primary D&O at $5M-$10M with appropriate Side A.

· Side B and C scaled to indemnify entity for securities-class-action exposure on Phase 2 readouts.

· Coordinate explicitly with clinical trial liability tower for trial-related claims.

· Employment practices liability scaled to active headcount.

· Fiduciary liability for any company-sponsored employee benefit plans.

Typical Texas premium: $40K-$120K annually for a Texas Phase 1-2 biotech.

Clinical-stage operators 12-24 months from anticipated public offering or SPAC merger.

IPO-readiness D&O

· Primary D&O at $10M-$25M, structured to support IPO underwriter representations.

· Pre-IPO Side A boosted to handle IPO-period exposure.

· Transactional D&O placement scoped at $25M-$50M, with separate runoff coverage.

· Public offering of securities insurance (POSI) for the offering itself.

· Coordinate with cyber for IPO-period heightened underwriter scrutiny.

· Coordinate with clinical trial liability and products liability where applicable.

Typical Texas premium: $120K-$280K annually for primary D&O at Texas IPO-readiness biotech. Transactional D&O placement at IPO is additional one-time premium of $300K-$800K depending on offering size.

Newly-public biotech operators in 12-36 months post-offering.

Post-IPO public biotech D&O

· Primary D&O at $15M-$50M with appropriate ABC structure.

· Side A coverage at elevated limits given heightened plaintiff bar attention to newly-public biotech.

· Coordinate with prior IPO-period transactional D&O runoff.

· Coordinate with clinical trial liability and products liability across the active pipeline.

· Cyber coordinated with D&O for cyber-event securities exposure.

Typical Texas premium: $200K-$650K annually for a Texas post-IPO biotech depending on market cap and pipeline.

Biotech with commercial product revenue, often post-BLA approval.

Commercial-stage biotech D&O

· Primary D&O at $25M-$100M plus with elevated Side A.

· Coordinate with products liability tower scaled to commercial product distribution.

· Patent infringement defense layered for IP-active operations.

· Cyber coordinated with D&O for cyber-event securities exposure plus consumer-facing data flows.

· Reputation risk and employment practices at commercial scale.

Typical Texas premium: $400K-$1.5M plus annually for a Texas commercial-stage biotech depending on product scale.

When to re-paper

The most common D&O architectural failure we see is biotech operators that bought a program at one stage and did not re-paper at the next transition. Pre-IND to Phase 1, Phase 2 readout, IPO filing, IPO completion, first BLA approval, and first commercial product launch each warrant D&O program re-evaluation. Operators that skip the IPO-readiness re-paper specifically end up with primary D&O insufficient to support the underwriter representations and with Side A coverage that is unable to cover individual director exposure if entity indemnification fails.

Biotech D&O review

A specialist will reach out by end of business day.

Request a coverage review